Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Infectious Diseases

Coccidioidomycosis (Infectious Diseases)

Last Updated: May 15, 2005
Email to a Colleague
Synonyms and related keywords: valley fever, desert fever, San Joaquin Valley fever, California fever, Coccidioides immitis infection, C immitis, Coccidioides posadasii, C posadasii, desert rheumatism, cocci

  AUTHOR INFORMATION Section 1 of 11    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Author: Edward L Arsura, MD, Chairman, Professor of Clincial Medicne,, Department of Internal Medicine, St.Vincent's Catholic Medical Center, Staten Island

Coauthor(s): Duane R Hospenthal, MD, PhD, Chief, Infectious Disease Service, Brooke Army Medical Center and Associate Professor, Department of Medicine, Uniformed Service University of Health Sciences

Edward L Arsura, MD, is a member of the following medical societies: American College of Physician Executives, American College of Physicians, American Federation for Medical Research, American Heart Association, American Medical Association, California Medical Association, Society of General Internal Medicine, and Southern Medical Association

Editor(s): Thomas Herchline, MD, Associate Professor, Department of Internal Medicine, Division of Infectious Disease, Wright State University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Thomas M Kerkering, MD, Professor of Medicine and Microbiology, Department of Internal Medicine, Division of Infectious Disease, Brody School of Medicine at East Carolina University; Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital; and Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Disclosure


  INTRODUCTION Section 2 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Background: Coccidioides immitis and Coccidioides posadasii are dimorphic fungi endemic to certain arid regions in the southwestern United States and in Mexico, Central America, and South America. The 2 species are morphologically identical but genetically and epidemiologically distinct. C immitis is geographically limited to California's San Joaquin valley region, whereas C posadasii is found in the desert southwest of the United States, Mexico, and South America. The manifestations of exposure to either organism are assumed to be identical; however, this hypothesis has not been formally tested.

The disease has numerous designations related to the location in which it is acquired (eg, valley fever, San Joaquin fever, desert fever, California fever) or clinical manifestations with which it presents (eg, desert rheumatism, coccidioidal granuloma). Most simply and commonly, the symptomatic infection is referred to as cocci.

Coccidioidomycosis was first recognized as a distinct disease entity in 1892. In 1900, coccidioidomycosis was identified as a fungal infection. The first documented case of coccidioidomycosis was diagnosed in an Argentinean soldier who had predominantly cutaneous manifestations. The actuality that coccidioidomycosis is not a rare, uniformly fatal infection was not appreciated until a medical student accidentally inhaled the Coccidioides organism and developed a nonfatal pulmonary illness accompanied by erythema nodosum. Researchers then noted the association between this presentation and the clinical condition known as San Joaquin Valley fever.

The importance of the illness increased during the 1930s and 1940s, with the influx of immigrants from the Midwest who arrived in the San Joaquin Valley of California to escape drought and to seek agricultural employment. The entry of thousands of military personnel building airstrips and participating in desert combat training during World War II also influenced the importance of the illness. The importance of coccidioidomycosis to the military led to many important studies on the pathogenic organisms and the epidemiology, clinical features, and diagnosis of coccidioidomycosis.

Interest in coccidioidomycosis has been renewed because of massive migration to the Sunbelt states. Areas of the country that were sparsely populated are now major population centers filled with individuals who are now susceptible to coccidioidomycosis. Phoenix and Tucson, Arizona; Bakersfield and Fresno, California; and El Paso, Texas, are prime examples. These locales also have a growing segment of individuals unusually susceptible to the most serious consequences of infection, specifically older and immunocompromised populations. Interest also has increased because of an explosion in the number of cases that occurred during the great coccidioidomycosis outbreak in California in 1991-1994.

The ecologic niche of the fungus is the lower Sonoran life zone. This zone is characterized by low elevations; scant rainfall (5-15 in/y); mild winters (40-54°F), hot summers; and sandy, alkaline soil with increased salinity. The Coccidioides organism is chiefly restricted to areas of the Western Hemisphere from latitudes 40° north to 40° south. Areas of highest endemicity are the southern-central portions of California (San Joaquin Valley), Arizona, southern New Mexico, western Texas, and northern Mexico. In addition, certain regions of Central America and South America have appropriate climatic conditions for the organism.

Infection is acquired via the respiratory tract. The number of cases of coccidioidomycosis in endemic regions rises sharply in the late summer and early fall. In the fall (ie, dry season), soil disturbances, either natural (wind) or man-made (agricultural endeavors, construction, archeological excavations) are likely to make the fungus airborne, enhancing the likelihood of its inhalation.

Coccidioidomycosis is considered to be an occupational hazard in endemic regions, and it is a compensable illness. Given the mode of transmission, outdoor activities are the primary risk factor. Infection may be acquired outside of endemic areas via transport of contaminated material. Alternatively, the infection may be acquired in endemic areas, but the initial symptom complex occurs after the patient has left the area.

Pathophysiology: Numerous studies have established that immunity mediated by T cells is critical to controlling the infection. T-cell activation and cytokine formation stimulate inflammatory cells and facilitate killing of the organism. T-helper type 1 (TH-1) cytokines, in particular interferon-gamma, promote macrophage killing of endospores.

A failure of the host to appropriately respond indicates either specific or generalized deficiency in cell-mediated immunity. This is clinically overt in patients who have conditions that impair cell-mediated immunity or in those who are using agents that interfere with T-cell function. Other factors can also cause failure of host response; examples are immune-complex formation and antigen overload.

Frequency:

  • In the US: An estimated 100,000 infections occur annually in the United States. An occasional case transmitted via fomites is reported outside of endemic areas.

    Several sharp upsurges in the incidence have occurred. The western migration of the 1930s and the influx of military personnel in the 1940s triggered notable increases. In 1978, the first true epidemic occurred after an unprecedented dust storm that originated in the lower end of the San Joaquin Valley, quadrupling the incidence of disease.

    The great coccidioidal epidemic occurred in California in 1991-1994. In 1992, this outbreak produced a peak of approximately 4200 cases, an increase of more than 14-fold from baseline. One explanation for the epidemic is that it occurred after a 5-year drought that was terminated by above-average rainfall. This rainfall allowed dormant arthrospores to germinate and be carried aloft by summer winds. At the same time, a marked influx of disease-naïve individuals into the area further set the stage for the epidemic.

    In areas of highest endemicity, the infection rate is approximately 2-4% per year. The prevalence in endemic areas has varied over time; the disease affects 24% of the population in the southern San Joaquin Valley at present. This figure is lower than findings from epidemiologic studies performed 50 years ago, when the results from skin tests for coccidioidal antigens were positive for 68% of the population. Positive skin test results are related to the duration of residence in endemic areas and to occupational and recreational exposure to dust.

Mortality/Morbidity: Potential complications of coccidioidomycosis are numerous (see Complications).

Race: Although no specific immunologic defect has been detected, when the Coccidioides organism infects African American, Hispanic, Filipino, and Asian individuals, they have an elevated risk of serious infection, with both pulmonary and disseminated disease. This risk persists when analyses are controlled for age, sex, additional demographic features, concurrent medical problems, duration of exposure, and occupation. When these populations are infected with the Coccidioides organism, their rate of skin-test positivity decreases, and their complement-fixation titer increases, compared with findings in the non-Hispanic white population.

  • One large study of 536 individuals demonstrated that 2.6% of non-Hispanic whites had dissemination, compared with 3.4% of Hispanic individuals, 7.3% of Filipinos, 22% of African Americans, 20% of Asians.
  • The elevated incidence of disease in these individuals does affect clinical decision making, particularly regarding the interpretation of symptoms and options for treatment.
  • A risk of coccidioidomycosis in patients treated with antagonists of tumor necrosis factor has been noted, adding this population to other immunosuppressed individuals (eg, those with HIV infection or organ transplants, among others). Substantial resources are being directed toward vaccine development.


  CLINICAL Section 3 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

History: As in much of clinical medicine, interpretation of the patient's history, physical findings, and clinical data, as directed by previous experience and knowledge, is crucial for focusing the diagnostic possibilities. More than in many other illnesses, the patient's travel history is of considerable importance, and even transient exposure to endemic areas greatly increases the likelihood of infection in a patient presenting with a compatible illness.

  • In symptomatic patients, the most frequent presentation is pulmonary infection. Symptoms in these individuals include the following:
    • Fever
    • Cough
    • Chest pain
    • Fatigue
    • Shortness of breath
    • Chills
    • Sputum production
    • Night sweats
    • Headache (common, even in the absence of meningitis)
  • These symptoms are nonspecific, but diagnosis may be aided by observing erythema nodosum, which is present in 25% of patients.

Physical: Findings on physical examination reflect the organ systems involved.

  • Pulmonary involvement may reveal evidence of consolidation with bronchial breath sounds, rales, rhonchi, dullness to percussion, and increased tactile and vocal fremitus.
  • Pleural effusion and pneumothorax yield the usual findings.
  • Meningitis is often accompanied by nuchal rigidity, photophobia, and alteration in cognitive functioning. Less frequent presentations include focal neurologic deficits, cranial nerve palsies, seizure and coma.
  • Ataxia or gait abnormalities may be present.
  • Localized percussion tenderness occurs in patients with bone disease.
  • If the vertebral column is involved, careful neurologic examination is warranted to detect cord impingement.
  • Joint involvement is usually monoarticular or oligoarticular. Physical findings are not helpful in differentiating coccidioidomycosis from other causes of monoarthritis or oligoarthritis.
  • Erythema nodosum appears as tender lesions, generally on the anterior surface of the lower extremities, though the lesions may occur virtually anywhere. The lesions are tender to palpation, erythematous, and 1-2 cm in diameter. Erythema multiforme occurs as relatively symmetric erythematous, expanding macules or papules that evolve into classic iris or target lesions, with bright red borders. Central vesicle formation is common.

Causes:

  • The Coccidioides organism grows in mycelial form in the soil of endemic areas.
    • As the mycelial structure matures, alternating hyphal cells either expand into barrel-shaped structures or shrink and die, producing the characteristic arthroconidia.
    • The arthroconidia are the infectious particles of coccidioidomycosis.
    • These conidia require little nutrition and can withstand extremes of heat, desiccation, and changes in soil salinity.
  • When the soil is disrupted, the arthroconidia can become airborne and, if inhaled by a susceptible host, produce infection.
    • Localized in the pulmonary acinus, the arthrospore sheds its outer coating, swells, and becomes a spherical structure, ie, the spherule.
    • The spherule is the parasitic stage of the organism, which reproduces by a process known as endosporulation. Rupture of the spherule leads to release of contained endospores, each of which matures into spherules, repeating the cycle.
    • If the organism is cultured, it reenters the mycelial phase, with hyphae formation.
  DIFFERENTIALS Section 4 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Acute Respiratory Distress Syndrome
Blastomycosis
Brucellosis
Cryptococcosis
Enteropathic Arthropathies
Eosinophilia
Eosinophilic Pneumonia
Histoplasmosis
Hodgkin Disease
Hypercalcemia
[Legionellosis]

Lymphoma, B-Cell
Mycetoma
Mycoplasma Infections
Myelophthisic Anemia
Paracoccidioidomycosis
Pericarditis, Acute
Pericarditis, Constrictive
Pneumonia, Bacterial
Pneumonia, Community-Acquired
Pneumonia, Fungal
Pneumonia, Viral
Pott Disease (Tuberculous Spondylitis)
Pulmonary Eosinophilia
Sarcoidosis
Septic Arthritis
Septic Shock
Solitary Pulmonary Nodule
Tuberculosis


Other Problems to be Considered:

Erythema nodosum
Erythema Multiforme

Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Pictures
Bibliography

Click for related images.

Related Articles
Acute Respiratory Distress Syndrome

Blastomycosis

Brucellosis

Cryptococcosis

Enteropathic Arthropathies

Eosinophilia

Eosinophilic Pneumonia

Histoplasmosis

Hodgkin Disease

Hypercalcemia

[Legionellosis]


Lymphoma, B-Cell

Mycetoma

Mycoplasma Infections

Myelophthisic Anemia

Paracoccidioidomycosis

Pericarditis, Acute

Pericarditis, Constrictive

Pneumonia, Bacterial

Pneumonia, Community-Acquired

Pneumonia, Fungal

Pneumonia, Viral

Pott Disease (Tuberculous Spondylitis)

Pulmonary Eosinophilia

Sarcoidosis

Septic Arthritis

Septic Shock

Solitary Pulmonary Nodule

Tuberculosis


Patient Education
Click here for patient education.



  WORKUP Section 5 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Lab Studies:

  • Direct examination
    • The diagnosis can be made by observing spherules (70 mm or smaller in diameter) that contain endospores in clinical material, including sputum or lesional smears and biopsy material.
    • Identification on smears may be made by using calcofluor white or cytologic stains.
    • Identification in biopsy material may be made by using standard hematoxylin and eosin or fungal stains (silver or periodic acid-Schiff).
  • Cultures
    • The most definitive method for diagnosis is isolation of the organism from clinical specimens. The fungus grows well on most common laboratory media within 5 days. Identification of colonial morphology, a white and cottony mold, is not adequate because other organisms have similar mycelial forms.
    • Observation of typical arthroconidia may be used to identify the Coccidioides organism.
    • Identification is usually confirmed with a commercially available nucleic acid (gene) probe. Confirmation with exoantigen testing may also be performed, though this test is no longer in common use because of the availability of nucleic acid probes.
    • Arthroconidia are infectious and therefore pose a significant risk to laboratory personnel. Always warn laboratory personnel in advance if coccidioidomycosis is suspected.
  • Serology
    • For more than half a century, detection of antibodies to coccidioidal antigens has been used to establish the diagnosis of coccidioidomycosis.
    • The 2 major antigens used to detect antibodies are the tube-precipitating (TP) antigens, so named because of the tube precipitant button at the bottom of the test tube when the test was originally performed, and an antigen that reacts with IgG, which fixes complement, the complement-fixation antigen.

      • TP antibodies are serum immunoglobulin (Ig) M antibodies to mycelial phase antigens that appear in more than 85% of patients with primary infection and are most commonly detected by means of enzyme immunoassay (EIA).

      • IgM antibodies are found early in infection, detected within the first week after the onset of symptoms and peaking after several weeks. In most patients, these antibodies dissipate within 6 months. A concern with IgM EIA antibodies is that the false-positive rate may be high, especially in conditions that stimulate humoral immunity.
    • IgG antibodies detected by means of complement fixation appear later, with results becoming positive in 85-90% of patients. However, this degree of serum positivity occurs only after 2 months of illness. The antibody usually disappears only after many months.
    • Quantification of IgM antibodies is of no prognostic value, whereas the degree of elevation of complement-fixation antibody is proportional to the disease extent. A titer of 1:32 or higher is a marker of dissemination.
  • Skin testing
    • The assessment of cutaneous reactivity to coccidioidal antigens has limited diagnostic utility because of its low sensitivity and specificity in endemic areas. Infected individuals may have negative results because of a lack of immune response, and healthy individuals may have positive results because of previous infection.
    • This is a delayed-type hypersensitivity reaction that appears 2-21 days after the onset of symptoms and precedes the appearance of serologic markers.
    • Cutaneous reactivity to coccidioidal antigens has epidemiologic and prognostic implications.
    • The lack of delayed-type hypersensitivity is a negative prognostic factor.

Imaging Studies:

  • In all patients with suspected or confirmed coccidioidomycosis, obtain a chest radiograph.
    • The most common finding is a localized infiltrate.
    • Less common findings are diffuse reticulonodular disease, pleural effusion, hilar adenopathy, single or multiple cavities (thin-walled and usually apical), miliary disease, or pneumothorax with associated pleural effusion may be seen.
  • Perform neuroimaging studies in patients with suspected meningitis.
    • MRI is more sensitive than other studies, yielding positive findings in approximately 75% of patients with coccidioidal meningitis, whereas CT has a yield of only 42%.
    • The 3 most common findings are hydrocephalus, basilar meningitis, and vascular occlusion. The detection of hydrocephalus and vascular occlusion has negative prognostic implications.
  • Skeletal images usually reveal an osteolytic lesion in patients with symptomatic bone disease. The MRI appearance of coccidioidomycosis is variable; findings may include heterogeneous marrow signal intensity and soft tissue involvement.
  • In patients with positive skeletal involvement or highly suspected osseous dissemination, a bone scan should be obtained to assess concurrent silent or multifocal osteomyelitis. Abnormal uptake on a bone scan should be investigated further with additional imaging modalities, such as CT or MRI.
  • CT imaging provides information on bony destruction that is more precise than that on MRI, but CT yields less information on spinal and soft tissue damage. MRI is the preferred modality if spinal cord impingement is considered. Either MRI or CT is useful to establish the extent of disease and to plan surgical debridement of the infected area.

Procedures:

  • Lumbar puncture is mandatory in patients with suspected meningitis.
  • Many physicians perform lumbar puncture in all patients with extrapulmonary disease or elevated compliment-fixation titers.
Histologic Findings: The predominant tissue reaction is granulomatous. In acute lesions, macrophages and polymorphonuclear neutrophils may be numerous. As lesions become chronic, fibrosis ensues. Caseation may occur.

The characteristic tissue form of the organism is the spherule. Pathogenicity of the organism is largely related to the resistance of the spherule to eradication by host defenses. Spherules and endospores produce no known toxins, and, as new spherules are propagated in infected tissue, progressive suppuration and tissue necrosis occurs. Neutrophils and mononuclear cells attempt phagocytosis of the organism, with giant cell formation occurring to attack larger fungal structures.

  TREATMENT Section 6 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Medical Care: Before the introduction of amphotericin B in 1957, no effective therapy for coccidioidomycosis existed. Although the introduction of azoles revolutionized therapy for cocci, amphotericin B remains the treatment of choice, either in the classic amphotericin B deoxycholate formulation or as a lipid formulation for severe infection. The lipid preparations were developed to lower the toxicity and provide efficacy at least equivalent to that of the parent compound.

Fluconazole can be used in the treatment of mild-to-moderate disease and, occasionally, life-threatening disease in patients who refuse amphotericin B or who have contraindications to its use. Because of its excellent penetration into the CSF, fluconazole has become the drug of choice for long-term therapy of meningeal infection.

Itraconazole 400 mg/d appears to have efficacy equal to that of fluconazole in the treatment of nonmeningeal infection. Serum levels of itraconazole are commonly obtained at the onset of long-term therapy, as its absorption is sometimes erratic and unpredictable. Although ketoconazole was initially used in the long-term treatment of nonmeningeal, extrapulmonary cocci, more potent, less toxic triazoles (fluconazole and itraconazole) have replaced it. Several case reports have alluded to the efficacy of 2 newer antifungal agents for disease refractory to first-line therapy: voriconazole, a triazole compound similar in structure to fluconazole, and caspofungin, a glucan synthesis inhibitor of the echinocandin structural class.

Several case series have highlighted the importance of corticosteroids in the treatment of patients with vasculitis; however, this information is anecdotal.

The treatment of septic shock associated with coccidioidomycosis relies on the use of antifungal therapy and appropriate resuscitative and supportive measures. However, the prognosis of patients with this entity is poor. Two patients with coccidioidomycosis and septic shock treated with drotrecogin alfa (activated protein C) were the first survivors reported.

Surgical Care: Surgical intervention may be required in cases of complicated pulmonary disease, bone disease, and hydrocephalus in which ventriculoperitoneal shunting may be required.

Consultations: Consultation with infectious disease or pulmonology specialists should be pursued if the treating physician does not have experience with this disease.
  MEDICATION Section 7 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

The goals of pharmacotherapy are to reduce morbidity, prevent complications, and eradicate the infection.

Drug Category: Antifungals -- Their mechanism of action involves preferentially binding to the primary fungal cell membrane sterol, ergosterol and increasing the permeability of the cell membrane, which in turn causes intracellular components to leak (amphotericin B), interfering with an enzyme is in the sterol biosynthesis pathway production of cell membrane ergosterol (azoles) or blocking fungal cell wall synthesis by inhibiting 1,3-beta glucan synthase (echinocandins).
Drug Name
Amphotericin B (Amphocin, Fungizone) -- Polyene antifungal agent for IV or intrathecal administration for severe and life-threatening infections. Metabolic clearance prolonged and not affected by renal or hepatic insufficiency. Produced by strain of Streptomyces nodosus; fungistatic or fungicidal. Binds to sterols (eg, ergosterol) in fungal cell membrane, causing intracellular components to leak, with subsequent cell death.

Three lipid formulations promising for reducing toxicity; currently licensed for use when amphotericin B fails or unacceptably toxic. How they compare with 24-h continuous infusion being investigated.

Significant reduction in nephrotoxicity and infusion-related reactions with continuous 24-h infusion vs conventional 2-6 h infusion.
Adult DoseIV: 0.5-0.7 mg/kg/d in 5% glucose over 2-6 h, often to total dose of 1.5-3 g (if amphotericin B is sole agent); test dose of 0.5-1.0 mg sometimes administered (not in acutely ill patients) to assess for possible severe constitutional response though this is severely questioned

Intrathecal: Start at 0.01-0.1 mg; titrate to 0.5 mg q48-72h; frequency adjusted to clinical symptoms and CSF results

Pediatric Dose0.25 mg/kg/d IV infused over 2-6 h, titrated to 1 mg/kg/d
ContraindicationsDocumented hypersensitivity
InteractionsAntineoplastic agents may enhance potential for renal toxicity, bronchospasm, and hypotension; corticosteroids, digitalis, and thiazides may potentiate hypokalemia; cyclosporine increases risk of renal toxicity
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsAdministration usually accompanied by fever, chills, and other constitutional signs; some attempt to limit symptoms with premedication with acetaminophen or aspirin, diphenhydramine, meperidine, or hydrocortisone; significant adverse effects include renal insufficiency (frequent, usually responds to saline volume repletion); reasonable guideline is cessation when serum creatinine level >3 mg/dL and reinstating when <2 mg/dL (or change to lipid-based preparation if creatinine level >2.5-3.0); nonanion gap acidosis related to distal acidification defect common, as is hypokalemia and hypomagnesemia
Drug Name
Fluconazole (Diflucan) -- Triazole antifungal agent to treat mild-to-moderate infections or severe or life-threatening infections in patients intolerant of amphotericin B. May be used for maintenance after course of amphotericin B in coccidioidal meningitis. Penetrates CSF well. Metabolic clearance is prolonged in renal dysfunction.
Adult Dose400 mg PO/IV qd; in some cases, 800 mg/d or higher have been given
Pediatric Dose3-6 mg/kg PO/IV qd
ContraindicationsDocumented hypersensitivity
InteractionsHydrochlorothiazides may increase levels; long-term coadministered rifampin may decrease levels; may increase theophylline, phenytoin, tolbutamide, cyclosporine, glyburide, and glipizide levels; effects of anticoagulants may increase with coadministration
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsMonitor closely if rash develops, and discontinue if lesions progress; may cause clinical hepatitis, cholestasis, and fulminant hepatic failure (including death) with underlying medical conditions (eg, AIDS, malignancy) and with multiple concomitant drugs; not recommended for nursing mothers; weigh convenience and efficacy of single-dose regimen for vaginal yeast infections vs increased incidence of adverse reactions reported with oral fluconazole vs intravaginal agents
Drug Name
Ketoconazole (Nizoral) -- Azole antifungal; used infrequently. Administer PO for mild-to-moderate infections that warrant treatment. Penetrates CSF poorly, but in unusual cases used to treat coccidioidal meningitis.
Adult Dose400 mg PO qd
Pediatric Dose<2 years: Not established
>2 years: 3.3-6.6 mg/kg PO qd
ContraindicationsDocumented hypersensitivity; fungal meningitis
InteractionsInterference with drugs metabolized in P450 pathway is significant concern; isoniazid may decrease bioavailability; coadministration of rifampin decreases effects of either; may increase effect of anticoagulants; may increase toxicity of corticosteroids and cyclosporine (can adjust cyclosporine dose); may decrease theophylline levels
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsHepatotoxicity (primarily hepatocellular damage or mixed hepatocellular and cholestatic changes) reported in about 1 case per 10,000 people and is major concern; may reversibly decrease corticosteroid levels (adverse effects avoided with 200-400 mg/d); administer antacids, anticholinergics, or H2-blockers at least 2 h after dose
Drug Name
Itraconazole (Sporanox) -- Triazole analogue of ketoconazole and preferred to parent compound because of enhanced safety and efficacy. Used for mild-to-moderate infections that warrant treatment. Penetrates CSF poorly, but successfully used to treat coccidioidal meningitis.
Adult Dose200-400 mg PO qd, administer with food to enhance absorption
Pediatric DoseNot established; suggested dose of 100 mg/d for systemic fungal infections
ContraindicationsDocumented hypersensitivity; coadministration with cisapride (no longer available) may cause adverse cardiovascular effects (possibly death)
InteractionsAntacids may reduce absorption; edema may occur with coadministration of calcium channel blockers (eg, amlodipine, nifedipine); hypoglycemia may occur with sulfonylureas; high doses may increase tacrolimus and cyclosporine plasma concentrations; rhabdomyolysis may occur with coadministration of HMG-CoA reductase inhibitors (lovastatin or simvastatin); coadministration with cisapride can cause cardiac rhythm abnormalities and death; may increase digoxin levels; coadministration may increase plasma levels of midazolam or triazolam; phenytoin and rifampin may reduce levels (phenytoin metabolism may be altered)
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsCaution in hepatic insufficiencies
Drug Name
Voriconazole (Vfend) -- Triazole antifungal structurally related to fluconazole for PO/IV administration. Some case reports detail in disseminated disease or meningitis refractory to first-line agents.
Adult Dose200 mg PO bid or 3-6 mg/kg IV q12h; actual range limited by limited experience
Pediatric DoseNot established; passage into breast milk unknown
ContraindicationsKnown hypersensitivity to drug or excipients; drug interactions with ritonavir and efavirenz; coadministration with rifampin, carbamazepine, and long-acting barbiturates (significantly decrease plasma levels); significant interactions with pimozide, quinidine and ergot alkaloids (do not coadminister)
InteractionsMetabolized by CYPP450 enzymes, CYP2C19, CYP2C9 and CYP3A4; may significantly increase plasma drug levels of tacrolimus, cyclosporine, methadone, phenytoin and omeprazole; anticoagulation may be markedly increased with warfarin
Pregnancy D - Unsafe in pregnancy
PrecautionsCaution in hepatic dysfunction; common adverse effects include visual disturbances, fever, rash, vomiting, nausea, diarrhea, and headache
  FOLLOW-UP Section 8 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Further Inpatient Care:

Further Outpatient Care:

Complications:

  MISCELLANEOUS Section 9 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Medical/Legal Pitfalls:

  • The most common issue is the erroneous assessment of a patient with meningitis with a lymphocytic pleocytosis as viral meningitis instead of coccidioidal meningitis.
    • The patient's travel history and area of residence have a major role in leading the clinician to the correct diagnosis.
    • Findings of eosinophils in the CSF or hypoglycorrhachia are important.
    • The progressive nature of the disease is inconsistent with a viral etiology.
  • The differential of erythema nodosum is extensive.
    • Coccidioidomycosis is perhaps one of the most significant associated conditions, and, once again, the patient's travel history and area of residence are important.
    • Patients with erythema nodosum generally have a benign course.
  • Pregnancy can pose a clinical challenge.
    • Some of the older literature recommends a consideration of abortion in pregnant women with coccidioidomycosis because of the virulent nature of the disease in this population.
    • One group examined a series of pregnant women with coccidioidomycosis. Although the disease complicated pregnancy, appropriate management led to satisfactory outcomes for the mother and child, suggesting that abortion need not be recommended.

Special Concerns:

  • Infection in immunocompromised individuals and specific groups of individuals who are not immunocompromised follows a more aggressive course than that in other groups.
    • Patients receiving immunosuppressive agents for cancer chemotherapy, organ transplantation, and/or autoimmune diseases or patients taking corticosteroids that impair cell-mediated immunity have a high frequency of dissemination. For example, organ transplant recipients have a significantly increased risk for dissemination, with the possibility of 25% developing disseminated disease. Previously resolved infections in organ transplant recipients reactivate at a rate of approximately 10% per year.
    • These rates mirror those observed in patients who are HIV positive and in the later stages of the illness, when opportunistic infection is likely.
    • In groups that are immunocompromised, progressive pulmonary disease is frequent, occurring in 40%.
    • Although skin reactivity to coccidioidal antigens may be impaired, serologic response in all patients, except those with the most profoundly immunocompromise, remains intact.
    • Older patients are at an increased risk for disseminated disease and diffuse progressive pulmonary disease. The mortality rate in patients older than 65 years is elevated, with one report describing a mortality rate of 15%.
    • Patients with diabetes also have an increased risk of diffuse progressive pulmonary disease and an elevated mortality rate.
  • Historically, pregnancy has been considered an extremely perilous time for infection with the Coccidioides organism.
    • Before the most recent epidemic, dissemination was believed to be 40-100 times more common in pregnant women than in the general population, and it was believed that 1 in every 8 women who acquired the infection during pregnancy would succumb to it. However, a study of a large number of individuals treated during the epidemic in California demonstrated that most pregnancies were carried to full term. Furthermore, pregnant women who develop infection and manifest erythema nodosum are extremely unlikely to have a negative outcome.
  PICTURES Section 10 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Caption: Picture 1. Chest radiograph with a thin-walled cavity in the left upper lobe consistent with coccidioidomycosis.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: Photo
Caption: Picture 2. Soft tissue abscess due to cocci.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: Photo
Caption: Picture 3. Pulmonary cocci spherule (Hematoxylin-eosin stain).
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: Photo
Caption: Picture 4. Pulmonary cocci spherule, periodic acid-Schiff stain.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: Photo
  BIBLIOGRAPHY Section 11 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

  • Arsura EL, Kilgore WB, Ratnayake SN: Erythema nodosum in pregnant patients with coccidioidomycosis. Clin Infect Dis 1998 Nov; 27(5): 1201-3[Medline].
  • Blair JE, Douglas DD: Coccidioidomycosis in liver transplant recipients relocating to an endemic area. . Dig Dis Sci 2004; 49: 1981-1985[Medline].
  • Crum NF, Lederman ER, Stafford CM: Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004; 83: 149-75[Medline].
  • Dewsnup DH, Galgiani JN, Graybill JR: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996 Feb 1; 124(3): 305-10[Medline].
  • Einstein HE, Johnson RH: Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis 1993 Mar; 16(3): 349-54[Medline].
  • Galgiani JN: Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med 1999 Feb 16; 130(4 Pt 1): 293-300[Medline].
  • Galgiani JN, Ampel NM, Catanzaro A: Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 658-61[Medline][Full Text].
  • Mirels LF, Stevens DA: Update on treatment of coccidioidomycosis [published erratum appears in West J Med 1997 Apr;166(4):291]. West J Med 1997 Jan; 166(1): 58-9[Medline].
  • Pappagianis D, Zimmer BL: Serology of coccidioidomycosis. Clin Microbiol Rev 1990 Jul; 3(3): 247-68[Medline].
  • Prabhu RM, Bonnell M, Currier BL: Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole . Clin Infect Dis 2004; 39: 74-77[Medline].
  • Ragland AS, Arsura E, Ismail Y: Eosinophilic pleocytosis in coccidioidal meningitis: frequency and significance. Am J Med 1993 Sep; 95(3): 254-7[Medline].
  • Stevens DA: Coccidioidomycosis. N Engl J Med 1995 Apr 20; 332(16): 1077-82[Medline].

Coccidioidomycosis (Infectious Diseases) excerpt